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Abstract: Chronic kidney disease (CKD) encompasses a group of diverse diseases that are associated
with accumulating kidney damage and a decline in glomerular filtration rate (GFR). These conditions
can be of an acquired or genetic nature and, in many cases, interactions between genetics and
the environment also play a role in disease manifestation and severity. In this review, we focus
on genetically inherited chronic kidney diseases and dissect the links between canonical and
non-canonical Wnt signalling, and this umbrella of conditions that result in kidney damage. Most of
the current evidence on the role of Wnt signalling in CKD is gathered from studies in polycystic kidney
disease (PKD) and nephronophthisis (NPHP) and reveals the involvement of β-catenin. Nevertheless,
recent findings have also linked planar cell polarity (PCP) signalling to CKD, with further studies
being required to fully understand the links and molecular mechanisms.
Keywords: Wnt signalling; polycystic kidney disease; nephronophthisis; beta-catenin; planar cell
polarity signalling
1. Chronic Kidney Disease (CKD)
Chronic kidney disease (CKD) is a term that denotes the presence of kidney damage, presenting
with abnormalities or a decline in kidney function. In order to distinguish between chronic and acute
kidney disease as well as assess the rate of decline in kidney function, kidney damage is measured
over the course of three months via the glomerular filtration rate (GFR) and it can be split across
five stages, depending on kidney function efficiency [1]. The first stage refers to a normal or high
GFR of > 90 mL/min [1], while the second stage refers to the initial display of an abnormal GFR,
which is slightly decreased (GFR 60–89 mL/min) [1]; this can be defined as the mild stage of CKD.
The third stage is a more moderate display of CKD, with the GFR being around half of the normal GFR
(30–59 mL/min) [1]. Stage four is a severe presentation of CKD and the GFR in this stage is around
15–29 mL/min. In comparison, stage five describes end-stage renal disease (ESRD), where the GFR is
<15 mL/min [1]. A number of kidney conditions, both inherited and acquired, have been associated
with reduced GFR and are a result of various genetic and environmental factors. The particular focus
of this review is to discuss the role of Wnt signalling in representative genetically inherited kidney
conditions and shed light on its significance, hoping to utilise this knowledge to inform personalised
medicine approaches.
2. The Clinical Symptoms of Genetically Inherited Chronic Kidney Diseases
Genetically inherited kidney diseases are an umbrella of various conditions that result from
mutations in genes that regulate kidney function (Table 1). These can be of dominant or recessive
inheritance and can manifest in individuals from a relatively young age. The most common of these
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conditions is autosomal dominant polycystic kidney disease (ADPKD). ADPKD is an inherited disorder
that affects around 12.5 million people in the world with no ethnic, racial or gender bias [2]. The disease
itself is one of the most common causes of end-stage renal disease (ESRD), with statistics showing
that ADPKD accounts for around 10% of all ESRD cases [2]. Symptoms of the disease include the
presentation of renal and hepatic cysts, together with hypertension, gross haematuria, nephrolithiasis,
urinary tract infection, shortness of breath and a general discomfort in the lower back [3]. Whilst
children with the disease are usually asymptomatic, symptoms of the disease tend to manifest in adults
between the ages of 30 and 50 [3]. ADPKD has been associated with mutations in two genes—PKD1 and
PKD2—either of which encode for Polycystin-1 (PC-1) and Polycystin-2 (PC-2), respectively. Evidence
has suggested that PKD1 mutations account for the majority of ADPKD cases, however, patients with
mutations in PKD2 are believed to have a better prognosis [4,5]. Unfortunately, no pharmacological
cure currently exists for ADPKD although a recent drug, Tolvaptan, has been shown to slow down the
progression of cysts [2].
Table 1. A brief summary, including symptoms and associated genes of the reported genetically
inherited chronic kidney diseases.
Disease Brief Description Associated Genes References
Autosomal Dominant
Polycystic Kidney
Disease (ADPKD)
- Autosomal dominant
- Affects around 12.5 million
people in the world.
- Symptoms include renal and
hepatic cysts, hypertension,
urinary tract infections.
- PKD1
- PKD2 [2–5]
Autosomal Recessive
Polycystic Kidney
Disease (ARPKD)
- Autosomal recessive
- Incidence rate: 1/20,000
- Affects neonates and infants.
- Symptoms include enlarged,
cystic kidneys, oligohydramnios,
hepatic fibrosis.
- PKHD1
- DZIP1L1 [6–10]
Nephronophthisis
(NPHP)
- Autosomal recessive
- Categorised into infantile,
juvenile and adolescent NPHP
- Symptoms include polyuria,
polydipsia, anaemia, reduced
kidney size and cysts in the
corticomedullary area.
- NPHP1
– NPHP20
- AHI1
[11–16]
Joubert Syndrome (JS)
- Autosomal recessive
- 20%-30% of JS patients
develop NPHP
- Symptoms include hypotonia,
hyperpnea, abnormal eye
movements, delays in
developmental abilities.
- NPHP1
- AHI1
- TMEM67
- CEP290
- RPGRIP1L
[16–20]
Meckel-Gruber
syndrome (MGS)
- 100% mortality rate
- Symptoms include polycystic
kidneys, polydactyly and
occipital encephalocele.
- Defective cilia/Wnt signaling
- NPHP3
- CEP290
- RPGRIP1L
[16–19,21–23]
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Table 1. Cont.
Disease Brief Description Associated Genes References
IgA nephropathy
(IgAN)
- Incidence rate of 2.5/100,000
- Clinical manifestations include
synpharyngitic macroscopic
haematuria, proteinuria.
- Varying prevalence based on
ethnicity and gender observed
with a possible increased risk in
familial relations, indicating a
genetic basis for IgAN
- Diagnosis typically dependent
on presence of granular
deposition of IgA in mesangium
by immunofluorescent analysis
on kidney biopsy samples
- Risk alleles in
the HLA
region at
chromosomes
6p21
and 1q32.
[24–28]
Focal and segmental
glomerulosclerosis
(FSGS)
- Incidence rate of 0.8/100,000 per
annum, worldwide
- Presentation of podocyte lesions
- Can be categorised into
idiopathic (primary) FSGS and
secondary FSGS
- Can also be categorised based
on cause of disease and
morphological appearance
of lesions
- Symptoms include oedema,
proteinuria, microscopic
haematuria, hypalbuminaemia
and hypertension.
- APOL1 [29–36]
Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a rare, genetic disorder with an
incidence rate of 1/20,000 [6]. It is a disease most common in neonates and infants, equally affecting
both boys and girls [6]. The disease manifests with a variety of abnormalities including bilateral
enlargement of both kidneys, presenting with fluid-filled cysts throughout the collecting ducts of the
kidney, oligohydramnios, hepatic fibrosis and respiratory insufficiency [6,7]. Consequently, patients
suffer from renal failure, hypertension, portal hypertension and pulmonary hypoplasia, with death
arising in around 30% of affected neonates [6]. ARPKD has been associated with mutations in Polycystic
Kidney and Hepatic Disease 1 (PKHD1), a gene encoding for a large, single-transmembrane protein,
Fibrocystin. Fibrocystin has been found to be localised to the primary cilium and basal body in the
kidneys, with expression also being observed in other organs, including the liver and lungs [8,9].
Recent evidence has also identified DZIP1L1 as a second gene associated with ARPKD, localised to the
centrioles and at the distal end of the basal body of the primary cilium [10].
Nephronophthisis (NPHP) is another autosomal recessive cystic kidney disease that is a leading
cause of ESRD in children and young adults [11]. The disease itself presents with symptoms such as
polyuria, polydipsia, anaemia, growth retardation and hypertension with characteristics including
reduced kidney size, the development of cysts in the corticomedullary area and loss of corticomedullary
differentiation [11,12]. NPHP can be categorised into three different forms, including juvenile NPHP,
which is the most common form of the disease, where patients tend to reach ESRD by the age of around
13; infantile NPHP, where patients reach ESRD before the age of 4; and adolescent NPHP where the
onset of ESRD is around 19 years of age [13–15]. Besides this, the diagnosis of NPHP is dependent on
the results observed in renal biopsies (including the presence of tubular atrophy, interstitial fibrosis,
thickening and attenuating of tubular basement membranes) and genetic testing [12]. To date, up to
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20 NPHP genes have been implicated in the disease—the most common being NPHP1, encoding
Nephrocystin-1 and NPHP2, encoding Inversin (Inv) [16]. Mutations in some of these NPHP genes,
including in NPHP6/CEP290, have been associated with other syndromes including Joubert syndrome
(JS) and Meckel–Gruber syndrome (MGS) with evidence displaying that around 20%–30% of JS patients
also develop NPHP [16–19]. JS is characterised by hypotonia, hyperpnea, abnormal eye movements,
delays in developmental abilities and ptosis. When presented with additional symptoms including
kidney disease, liver disease and skeletal abnormalities, the disease is referred to as ‘Joubert syndrome
and related disorders (JSRD) [20]. In comparison, MGS presents with symptoms including polycystic
kidneys, polydactyly and occipital encephalocele with 100% mortality rate [21]. Both JS and MGS are
inherited in an autosomal recessive pattern and have been categorised alongside ADPKD, ARPKD
and NPHP as ‘ciliopathies’, a term which denotes defects in primary cilia [20,21]. Primary cilia have
been implicated in kidney development and disease and are linked to proteins that are associated
with cystic renal diseases, including the diseases mentioned above [22]. Signalling via the primary
cilium is also thought to be a crucial process and evidence has found that defects in cilia can impact
cilia-associated signalling pathways, including Wnt signalling [23].
IgA nephropathy (IgAN) is one of the most common forms of glomerulonephritis and another
leading cause of CKD and ESRD, with an incidence rate of 2.5/100,000 [24]. Clinical manifestations of
the disease are variable with common presentations including microscopic/macroscopic haematuria,
together with the presentation of proteinuria [25]. Another common characteristic is synpharyngitic
macroscopic haematuria, where episodic haematuria follows an upper respiratory tract infection [25].
The diagnosis of IgAN is dependent on immunofluorescent analysis on kidney biopsy samples, where
granular deposition of IgA in mesangium is usually observed [25]. Despite the continuous research
trying to establish the cause and genetic basis of IgAN, there is no definitive causative gene(s) that has
been established to date, rather indications of genetic factors involved in the disease [26]. Varying
prevalence of IgAN has been observed in different ethnic groups, with a higher prevalence of IgAN
found in Asian populations compared to Europe and North America. In addition, in Europe, there is
higher prevalence of IgAN in men than women and an increased risk of IgAN in relatives of patients
in Europe—this is not observed in Asia [26,27]. It is key to note that there may be a limitation in this
finding, due to differences in the criteria for the use of renal biopsies across different geographical
locations. Recently, there has been an increase in renal biopsy use in Europe, which may account for the
increase in IgAN prevalence observed [26]. Despite this, genome-wide association studies in European
and South-East Asian populations have highlighted risk alleles in the HLA region at chromosome 6p21
and chromosome 1q32 [28].
Focal and segmental glomerulosclerosis (FSGS), a common cause of nephrotic syndrome,
refers to the presentation of scarring on certain parts of the glomeruli, whilst other parts remain
unaffected [29]. In the US, the incidence rate has been reported at around 7/1,000,000, with the
number of ESRD cases being accounted for by FSGS relatively increasing, whilst McGrogan et al.
reported the incidence rate for FSGS as around 0.8/100,000 per annum, worldwide [24,30]. Clinical
symptoms of the disease include oedema, proteinuria, microscopic haematuria, hypalbuminaemia and
hypertension, however, a definitive diagnosis is dependent on analysis of a kidney biopsy sample [29].
FSGS can be sub-categorised based on a classification system that considers the underlying cause
of the disease. This includes idiopathic (primary) FSGS and secondary FSGS, which account for
genetic/virus-associated forms [31]. Despite this, Rosenberg and Kopp have categorised FSGS in
a similar manner into six different forms including primary FSGS, adaptive FSGS, APOL1 FSGS,
genetic FSGS, infection/inflammation-associated FSGS and medication-associated FSGS, whilst the
disease can also be classified based on the morphological appearance of FSGS lesions (perihilar,
cellular, tip, collapsing and not otherwise specified) [29,32–34]. Several factors are believed to be
involved in the pathogenesis of the disease, which can vary, but the result of these factors is damage
to podocytes/podocyte lesions, consequently resulting in the phenotypic characteristics presented in
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FSGS [35]. Current research is still working on identifying an underlying genetic mechanism of the
disease, with recent findings in African descent patients associating FSGS with variants in APOL1 [36].
3. The Role of Upstream Wnt Components in Genetic CKD
In recent years, there has been an accumulation in the number of studies implicating Wnt ligands
and components of the Wnt signalling pathway with CKD (Table 2). Immunohistochemical evidence
of kidney biopsy samples has highlighted the presence of several Wnt proteins in common CKDs,
including in IgAN and FSGS [37]. The majority of Wnt ligands expressed in the fibrotic kidney,
including Wnt1, Wnt2, Wnt4, Wnt5a, Wnt9b and Wnt10b, were localised in the tubular epithelium [37].
Renal tubule specific inhibition of Wnt secretion resulted in the inhibition of fibroblast gene expression
activation, as well as the improvement in kidney fibrosis, and thus it was concluded that there may be
a role for tubule-derived Wnt proteins in fibroblast activation and kidney fibrosis [37]. It is key to note
that some research has suggested that certain Wnt ligands are predominantly activated in either the
canonical or non-canonical Wnt signalling pathway, however, there has been evidence associating Wnt
ligands, such as Wnt3a and Wnt5a, to both signalling pathways [38–41].
Table 2. Wnt components have roles in various chronic kidney diseases (CKDs).
Wnt Component Disease Model References
WNT1 FSGS Human [42]
WNT4
PKD, Membranous
Nephropathy Human, mouse [43,44]
WNT5A ARPKD, ESRD Human [45–47]
WNT9B PKD Mouse [48,49]
WNT11 PKD Mouse [50]
LRP5 ADPKD Human, cell line (HEK293) [51]
LRP6 PKD Mouse [52]
β-catenin ADPKD, IgAN, FSGS
Human, mouse, cell line (renal
collecting duct cell line) [42,53–55]
NPHP2/Inversin ADPKD, IgAN, NPHP Human [53]
VANGL2 ARPKD Human [47]
CELSR2 JS Human [56]
SCRIBBLE ARPKD Human [47]
One of the key Wnt ligands that has an established role in the pathogenesis of CKD and is
believed to predominantly act through the canonical Wnt signalling pathway is Wnt1 [38]. Published
data have suggested that the overexpression of Wnt1 and active β-catenin is specifically associated
with FSGS and diabetic nephropathy (DN) in glomerular podocytes [42]. This comes from evidence
whereby the expression of Wnt1 and active β-catenin was observed in DN and FSGS kidneys, whilst
that expression was not detected in normal human kidney glomeruli [42]. Further implicating Wnt1
and the canonical Wnt signalling pathway to CKD is the role they play in podocyte dysfunction and
the exacerbation of albuminuria [42]. The upregulation of Wnt1 in vivo, which activated glomerular
β-catenin, as well as the pharmacologic activation of β-catenin, seemed to induce albuminuria, whilst
also presenting with podocyte lesions [42]. To strengthen this finding, upon treatment with an
antagonist of Wnt signalling, Dickkopf (DKK1), the presentation of podocyte injury and albuminuria
improved [42,57]. DKK proteins antagonise Wnt signalling by binding and internalising low-density
lipoprotein-receptor-related protein 5 (LRP5) or 6 (LRP6) [57].
Besides Wnt1, other Wnt ligands have been shown to play a role in kidney development and have
a known involvement in genetic kidney diseases. One such example is Wnt4, which is required for
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the conversion of metanephric mesenchyme (MM) to epithelia that form the nephron. Wnt4-induced
tubule formation in MM cells and studies in genetically modified mice showed Wnt4 expression
in pretubular aggregates [58]. Wnt4-induced tubulogenesis was mediated by the non-canonical
Wnt/calcium pathway and an influx of Ca2+ occurred when MM cells were induced by Wnt4 [58]. Wnt4
expression was observed as early as stage 25 and was halted at stage 35 in Xenopus embryos upon the
formation of epithelial structures [59]. In Pkd1−/− mice, Wnt4 expression was rapidly downregulated
by embryonic day (E)14.5 and at E15.5 renal and pancreatic cysts had developed [43]. There is also
evidence that the transcription factor GLIS2 regulates Wnt4 expression, with homozygous mutant
GLIS2-/- mice and GLIS2-knockdown IMDC3 cells showing upregulated Wnt4 expression and GLIS2
mutations linked to Nephronophthisis 7 in humans and mice [60]. A recent study performed by
Kiewisz et al. investigated Wnt4 expression in several glomerular diseases and most importantly at
various stages of CKD [44]. WNT4 mRNA and protein expression was absent in normal adult kidneys,
until renal injury or onset of kidney diseases caused the activation of WNT4 expression. A consistent
increase in WNT4 expression was observed in all CKD stages. In addition, a small significant decrease
was detected between stage 2 and 3. As well as this, the greatest WNT4 expression was seen in
membranous nephropathy compared to Lupus nephritis and IgAN/FSGS [44].
Wnt5a is another Wnt ligand with demonstrated functions in the kidney. Bilateral duplex kidneys
were observed in Wnt5a fl/+;T-Cre and Wnt5a fl/∆;T-Cre mice along with shortened tail, limbs, digits,
face, and genitals [61]. Increased Wnt5a expression in zebrafish led to kidney cyst formation in all
nephron structures, signifying Wnt5a’s importance for correct kidney morphogenesis [62]. A recent
study demonstrated that the upregulation of WNT5A expression was noted in ARPKD compared
to age-matched normal paediatric kidneys, proposing its novel involvement in ARPKD through
interactions of Fibrocystin with ATMIN, an effector PCP transcription factor [45]. A recent clinical study
assessed vascular calcification in 41 patients with ESRD and revealed an upregulation in WNT5A and
β-CATENIN expression in radial arteries obtained during arteriovenous fistula surgery, concluding
that expression of WNT5A was an independent risk factor that could result in vascular calcification [46].
To further this, humans and mice exhibiting loss of function (LOF) of WNT5A presented multiple-organ
defects and patients harbouring the most prominent WNT5A LOF variants all exhibited kidney
malformation [63].
Wnt9b is a crucial Wnt ligand that plays a role in both canonical Wnt signalling and non-canonical
Wnt/PCP signalling. This comes from evidence that displays that mis-expression of Wnt9b in
Six2-positive cells disrupts kidney function by activating canonical Wnt signalling in Wnt9b transgenic
mice [48]. As well as this, researchers highlighted the upregulation of canonical Wnt signalling, together
with the presence of renal cysts throughout the nephron, further supporting the idea that disruption
of canonical Wnt signalling can result in cystic disease [48]. Despite this, other evidence has also
highlighted that regulation of Wnt9b is crucial for PCP in the epithelium of the kidney and that
depleted Wnt9b resulted in an increased diameter in tubules [49]. Similarly, attenuation of Wnt9b
resulted in renal cystogenesis [49].
Wnt11 binds to Frizzled (Fz) 4 to induce canonical and non-canonical signalling in the same
cell line (human embryonic kidney 293 (HEK293)), whereas the binding of Wnt11 and Fz8 induces
the non-canonical signaling pathway only [64]. In Wnt11tm1a/tm1a mice, the tubular morphology was
disrupted, and glomerular cysts were present. The disruption in tubular morphology caused the
population of normal nephrons in Wnt11-/- mice to be reduced by half at 6 weeks post birth [50].
Additionally, a noticeable increase in the size of the glomeruli and renal capsules was observed, along
with a 28% decrease in kidney size [50]. Examination of C57BL/6 Wnt11-/- mice revealed that the
kidneys were hypoplastic and small cysts had formed by E16.5. Decreased cell population and reduced
expression of stromal progenitor markers, e.g., Hox10 and Foxd1 were also observed in Wnt11-/- mice at
E16.5 [65]. It was postulated that the absence of Wnt11 in Wnt11-/- mice was believed to trigger the
downregulation of the following genes: Six2, Wnt9b, Gdnf, and Foxd1 [50]. The conservation of renal
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architecture in a smaller kidney volume was similarly observed in Wnt11-/- embryos and Fz4-/- /Fz8-/-
embryos [64].
4. Wnt Signalling Receptor Involvement in CKD
Wnt signalling activation results after a Wnt ligand binds to a Fz receptor, sometimes also in
the presence of other co-receptors. To date, there are a total of 10 identified mammalian Fz genes,
with expression of all these being observed in the human kidney [66–73]. A 30% decrease in kidney size
was observed in homozygous mutant Fz4 and Fz8 mice, whereby renal architecture was preserved with
no evidence of cyst formation, but a reduction in ureteric bud branching [64]. A significant upregulation
of Fz3 and downstream effector CDC42 was observed in Pkd1 knockout (KO) cystic mouse kidneys [74].
Fz3 expression increased before or simultaneously with the rate of cyst formation and it was postulated
that the increase in Fz3 contributed to the growth and enlargement of the cysts [74].
LRP5/LRP6 are crucial co-receptors of the canonical Wnt signalling pathway, since its activation
is dependent on the binding of a canonical Wnt ligand to a Fz receptor in the presence of these
co-receptors [75]. Mutations in LRP5 have been linked to hepatic cystogenesis and may be associated
with ADPKD, further emphasising the role of the key canonical Wnt signalling co-receptors LRP5/LRP6
in cystogenesis and PKD [51,76]. Cnossen et al. observed four LRP5 variants in sporadic ADPKD
patients, whilst reduced activation of canonical Wnt signalling and altered Wnt target gene expression
was detected upon transfection of HEK293 cells with mutant LRP5 [51,76]. This included increased
gene expression of target genes including adenomatous polyposis coli (APC), glycogen synthase kinase
(GSK3β), axis inhibitor-1/2 (AXIN-1/AXIN-2) and c-Myc, whilst, in the presence of Wnt3a, decreased
gene expression was observed for GSK3β, AXIN-1, AXIN-2 and c-Myc [76]. Furthermore, mutant mouse
embryos whereby an insertion mutation links the first 321 amino acids of the LRP6 protein with the
βgeo reporter gene have been demonstrated to be embryonic lethal and result in polycystic kidneys [77].
In addition to this, LRP6 KO in another mouse study displayed similar results [52]. At E11.5, fewer
mesonephric tubules were detected in LRP6 KO mice in comparison to littermate controls, and at E18.5,
all LRP6 KO mouse kidneys were hypoplastic and exhibited several cysts [52]. Recent evidence has
also highlighted an interaction in PKD between LRP6 and AHI1, a gene that encodes for the protein
Jouberin (Jbn) and that has been associated with NPHP [52,78]. Jbn is believed to interact with and
facilitate β-catenin nuclear accumulation, whilst loss of the protein resulted in a decrease in β-catenin
function [52,78], with Jbn and LRP6 potentially sharing the same signalling pathway, since renal
atrophy and renal cysts were seen in heterozygous Ahi1+/-; LRP6+/- and homozygote Ahi1-/- mice [79].
Aside from canonical Wnt receptors, core PCP receptors that are evolutionarily conserved from
Drosophila to mammals have been demonstrated to have a crucial involvement in the kidney. Conserved
PCP proteins have further been reported to influence the function of cilia, hence why mutations in
PCP genes have been shown to cause ciliopathies ranging from PKD to rarer genetic disorders like
MGS, Bardet–Bieldl syndrome and NPHP [80]. It has been shown that Vangl2 is normally expressed
in epithelial podocytes that regulate normal differentiation, which later induces the formation of the
glomeruli, nephron tubules and collecting duct tubules [81]. Point mutation of Vangl2 in homozygous
loop-tail (Lp) mice resulted in malformed kidneys alongside dysmorphic glomeruli [81]. Immature
glomeruli and hypoplastic medulla were observed in Vangl2Lp/Lp at E17.5; interestingly, heterozygous
Vangl2Lp/+ mouse organs appeared normal and retained morphological structures. Immunostaining of
Vangl2Lp/Lp fetal kidneys revealed the presence of primary cilia, implying that the absence of Vangl2
does not affect ciliogenesis [82]. Recent work has revealed a genetic interaction between Vangl2 and
Atmin [45]. Immunostaining of E13.5 AtminGpg6/Gpg6 embryonic kidneys revealed a downregulation of
Vangl2 expression, although Vangl2 mRNA levels remained unchanged. In addition, the degree of
craniorachischisis in both AtminGpg6/+ and Vangl2Lp/+ mutant mice was noted to be similar, with double
heterozygous mice revealing a genetic interaction [45]. An upregulation of VANGL2 expression was
observed in human ARPKD samples compared to normal age-matched kidneys [47].
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The published literature shows that Celsr1 is strongly involved with epithelial planar cell
polarity, whereas Celsr2 and Celsr3 are often associated with ciliogenesis and neural development,
respectively [83]. Interestingly, CELSR1-3 show variable expression in the kidneys, lungs, reproductive
systems, gastrointestinal and the skin [83]. Celsr1crsh/crsh mice displayed severely dysmorphic kidneys
with dilated tubules, immature glomeruli and immature tubular architecture [84]. To further support
the significance of CELSR in relation to the manifestation of diseases, an extensive clinical evaluation
of 100 patients from 86 families diagnosed with JS discovered that CELSR2 was a novel pathogenic
variant that was not previously associated with the manifestation of JS, although it only accounted for
a small proportion (1%) of patients [56].
Finally, decreased SCRIBBLE expression was observed in ADPKD cell lines and Pkd2 morphant
zebrafish, with loss of Scribble causing pronephric ducts to be dilated [85]. Scribble colocalised with
PC2 and this interaction reduced cyst growth in Pkd2 morphants, revealing a novel role for Scribble
in cyst formation in ADPKD via the YAP pathway [85]. Interestingly, an upregulation of SCRIBBLE
was observed in human ARPKD kidney biopsies; likewise, in Pkhd1 knockdown mIMDC3 cells,
a 60% increase in Scribble mRNA expression was detected, suggesting links between Scribble and
Fibrocystin in ARPKD [47]. Furthermore, knockdown of Scribble caused the depletion of Fat1, leading
to cyst formation during zebrafish pronephros development and suggesting an overlap in signalling
cascades [86].
5. The Role of β-Catenin in Genetic CKD
Despite playing a crucial role in organ development, canonical Wnt signalling is comparatively
inactive in normal adult kidneys [87], but becomes activated after renal injury [88]. Research highlights
a protective role for canonical Wnt signalling after acute kidney injury (AKI) however, despite this,
evidence has demonstrated that continuous β-catenin activation could become detrimental and lead
to CKD [88–90]. It has been observed that the role that β-catenin plays in disease is similar to the
role it plays in development, whereby although β-catenin is necessary to initiate nephrogenesis,
sustained β-catenin action could result in defective epithelialisation [89]. In a study by Xiao et al.
where researchers used moderate (20 min) and severe (30 min) ischaemia reperfusion injury (IRI)
mice, it was found that the moderate IRI in mice led to acute kidney failure and β-catenin activation,
followed by restoration of kidney morphology and function [90]. In comparison, the severe IRI mice
displayed continuous β-catenin activation and an eventual appearance of CKD, presented by renal
fibrosis [90]. This upregulation of β-catenin has proven to be a pathologic feature in several fibrotic
CKDs including obstructive nephropathy, DN, Adriamycin (ADR) nephropathy, remnant kidneys
after 5/6 nephrectomy, PKD and chronic allograft nephropathy [42,91–95]. Besides this, an increase in
nuclear accumulation of β-catenin has been observed in the peripheral blood leukocytes from IgAN
patients, whilst evidence has also displayed the activation of the canonical Wnt signalling pathway in
lupus nephritis patients [53,96]. This presence of β-catenin activation has been consistent throughout
all research in animal models of CKD [88].
Another key focus of research has been identifying specific downstream targets of the canonical
Wnt signalling pathway in relation to kidney disease. Evidence has implicated multiple downstream
targets of β-catenin in kidney injury and fibrotic CKD, including matrix metalloproteinase-7 (MMP-7)
and plasminogen activator inhibitor-1 (PAI-1) [91]. MMP-7, a target gene of Wnt signalling with a role
in epithelial repair and host defence, is usually expressed at low levels [91,93]. Upon kidney injury,
it has been demonstrated that MMP-7 is induced and its expression is in fact increased in diseases,
such as PKD and obstructive nephropathy [93]. Levels of renal MMP-7 have been found to correlate
with Wnt/β-catenin activity in several CKD models [97].
As well as this, PAI-1 which is a secreted acute-phase glycoprotein, is also usually produced
in low levels. PAI-1 is a target gene of β-catenin signaling, since the promoter region of PAI-1
contains a TCF/LEF-binding site [98]. Upregulating β-catenin has been shown to stimulate PAI-1
expression, whilst inhibition of β-catenin signalling/disruption of the TCF/LEF-binding site counteracts
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this [98]. In chronic kidney diseases such as DN, membranous nephropathy, FSGS and crescentic
glomerulonephritis, PAI-1 expression becomes upregulated [99]. This evidence highlights PAI-1 as an
important downstream target of β-catenin signalling in renal injury.
Whilst β-catenin signalling has been implicated in podocyte dysfunction, recent evidence has
suggested that it could also cause podocyte injury by inducing transient receptor potential cation
channel 6 (TRPC6), a calcium channel localised to podocytes, through exposure to high glucose [100].
Further evidence found that high-glucose-induced podocyte lesions improved upon inhibition of the
canonical Wnt signalling pathway via DKK1 treatment, which also inhibited TRPC6 expression [100].
It is key to note that TRPC6 missense mutations have been associated with FSGS and thus, this research
could demonstrate another way by which the canonical Wnt signalling pathway could cause podocyte
dysfunction [101]. It is also important to note that whilst several factors result in the activation of the
canonical Wnt signalling pathway, there are a number of antagonists of Wnt signalling, including
soluble Frizzled-related proteins (sFRPs), Wnt inhibitory factor and the family of DKK proteins.
As mentioned previously, DKK proteins antagonise Wnt signalling by binding and internalising
LRP5/6, however, antagonists like sFRPs and Wnt inhibitory factor work by binding to Wnt proteins
and consequently preventing the binding of Wnt proteins to Fz receptors [57,91]. By using this
information, researchers have found that inhibiting β-catenin activation using DKK1 ameliorates
kidney fibrosis in mouse models [92]. Further supporting this argument is a study that revealed loss of
Klotho, another antagonist of β-catenin which is usually expressed in adult kidneys, in mouse models
of CKD [102]. It was found that when Klotho was expressed in vivo, fibrotic lesions and kidney injury
bettered [102].
Surendran et al. found that after Unilateral Ureteral Obstruction (UUO), the expression of
both sFRP4 and DKK1 increased, whilst the administration of recombinant sFRP4 attenuated renal
fibrosis [93]. Whilst further investigations found that these data correlate with a faster decline in renal
function, other research has displayed that a decrease in sFRP4 relates to an increase in β-catenin
signalling and an increase in the progression of renal fibrosis [93,103]. Corresponding with this,
it was found that an increase in sFRP4 led to a decrease in β-catenin signalling and a decrease in the
progression of renal fibrosis [93,103]. Elevated levels of sFRP4 expression have also been observed
in human patients of ADPKD and animal models of cystic kidney disease, including in NPHP,
highlighting a relationship between the induction of sFRP4 expression and renal cystogenesis [104].
Depletion of another Wnt antagonist, Dapper3, which colocalises with Dishevelled (Dvl) and forms a
complex with cytoplasmic proteins Axin, glycogen synthase kinase-3 (GSK3), casein kinase 1 (CK1)
and β-catenin causes the accumulation of Dvl2 and β-catenin and aggravates the fibrotic phenotype
after UUO [105,106]. Tan et al. have suggested that RAS genes also have TCF/LEF-binding sites and are
thus regulated by β-catenin signalling [91]. The group’s data shows that RAS genes are upregulated by
β-catenin in vitro and in vivo and that the upregulation can be blocked by β-catenin inhibitors, such as
ICG-001 [91,107]. Other evidence has found that canonical Wnt signalling inhibition via XAV939,
a tankyrase inhibitor that promotes β-catenin degradation and LGK974, a Porcupine inhibitor that
blocks lipid modification of Wnt proteins, delays the progression of renal cystogenesis and reduces
elevated levels of β-catenin and of Wnt target genes, Axin-2, c-Myc and cyclin D1 in mutant mice [108].
6. Links between Wnt Signalling, PKD and NPHP
Aside from the role of Wnt proteins in kidney development and function, various research findings
exist that link Wnt signalling to PKD and NPHP, two of the greatest groups of inherited cystic kidney
diseases (Figure 1). The dysregulation of β-catenin was associated with cystic kidney disease in mice
and other ADPKD models [51,88,109,110]. In a study where Pkd2 was knocked out from a renal
collecting duct cell line, there was evidence of ciliogenesis defects, together with increased β-catenin
and AXIN-2 and c-Myc expression [55,111,112]. Further supporting this, is evidence from a Pkd2
KO mouse line where the mutant mouse presented with kidney cysts, whilst the kidney tissue also
demonstrated elevated levels of active, nuclear and total β-catenin (Ctnnb1) proteins alongside Axin-2,
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c-Myc and cyclin D1 proteins [108]. In the same study, loss of one Ctnnb1 allele rescued the renal cystic
phenotype and reduced the increased levels of Wnt target genes Axin-2, c-Myc and cyclin D1 [108].
In another study, the conditional inactivation of APC, a tumour suppressor that forms a key part of the
multiprotein β-catenin destruction complex in the canonical Wnt signalling pathway resulted in cystic
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Further highlighting the link between PKD and canonical Wnt signalling is a study that investigates
the association between Aquaporin-1 (AQP1), a water channel protein with expression in the kidney,
and Wnt signalling [113]. Upon overexpressing AQP1 in a mammalian cell line, Madin-Darby
Canine Kidney (MDCK), reduced expression of β-catenin and cyclin D1 was observed [113]. As well
as this, the study highlighted an interaction between AQP1 and various canonical Wnt proteins
including β-catenin, GSK3β, LRP6 and xin1 [113]. A MDCK cyst model also demonstrated that the
overexpression of AQP1 inhibited c t sis and increased MDCK cell branching [113]. Upon KO
of AQP1 in a PKD mouse model, i tors observed an increase in kidney size and cyst formation,
together with increased Wnt sign lli tivity in the kidney [113]. Thus, it can be oncluded that
there is a relationship between canonical nt signalling and PKD.
It is important to note that evidence has implicated the Polycystin complex as a Wnt receptor
through research that found the binding of Wnt ligands to the extracellular domain of PKD1 [114].
This includes Wnt ligands that act predominantly through the canonical Wnt signalling pathway
(Wnt3a), non-canonical Wnt signalling pathway (Wnt5a) or both (Wnt9b and Wnt4) [114]. As well as
this, the study found that the mediation of pronephric tubule formation in Xenopus is regulated by
Wnt9a, Pkd1, and Dvl2 [114]. This study demonstrated that in Pkd1 -/- cells, a downregulation of Dvl2
was observed [114]. Further experimental studies revealed that Dvl2 co-immunoprecipitated with Pkd1,
implying that direct binding occurs. Additionally, knockdown of Dvl2 and Pkd1 in Xenopus resulted in
similar cystic kidney ph not pes [114]. Furthermore, a study performe a few years prior revealed
that Xenopus embryos inje ted wit mutant Dvl2 pr sented broader wolffian ducts (~1.5x wider) and
that the concertina-shaped ducts curved towards the cloaca instead of running in a straight line [115].
Inversin, a key protein encoded by NPHP2, is proposed to act as a molecular switch between the
canonical and non-canonical Wnt/PCP signalling pathway [116]. It has been suggested that Inversin
forms a complex with Dvl and prevents the action of the canonical Wnt signalling pathway upstream of
the β-catenin degradation complex [116]. Phenotypes described in Fz8-/- Xenopus resemble phenotypes
exhibited when Inversin was depleted in other animal models [117]. It was also postulated that via the
non-canonical pathway, Inversin colocalised with Dvl in the membranes of polarised renal epithelial
cells. It was demonstrated that, in response to Fz receptors, Inversin induced the translocation of Dvl,
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and that during pronephros development, Inversin acted downstream of Fz8 induction. Furthermore,
it was revealed that the overexpression of Inversin in Fz8 depleted Xenopus was able to rescue defects
during pronephros development [117]. Kidney defects and cyst formation in the pancreas and kidneys
were phenotypes described in inv-/- mice [118]. Evidence showed that Inversin localised to the primary
cilium in mouse embryonic fibroblast (MEFs) derived from inv-/- mice. The colocalisation of Fz3
was detected in the primary cilium of inv-/- and inv+/+ mice MEFs, implying that the induction of
receptors in the cilium may regulate Wnt signalling and that Fz3 could be independent of inversin
ciliary targeting [118].
The collective phenotypes exhibited when NPHP2 is disrupted include basement membrane
abnormalities, renal interstitial fibrosis, kidney enlargement and cyst development [119]. The deletion of
exons 3-11 of Nphp2 in mice resulted in enlarged kidneys with widespread cyst formation alongside situs
inversus and dysplasia of pancreatic islet cells [119]. The comparison of histological studies performed
on inv/inv mouse and infantile NPHP2 samples revealed characteristic phenotypes commonly present
in NPHP, e.g., interstitial fibrosis, tubular cell atrophy, and tubular cysts. In addition, the identified
features resemble those observed in ADPKD; such as enlarged kidney and abnormalities in the
basement membrane. Interestingly, this study demonstrated that NPHP2 is a causative gene which
causes NPHP-2 with or without situs inversus. Likewise, cystic phenotypes were identified in inv
mutant zebrafish. Immunoblotting confirmed the co-precipitation of Inv and nephrocystin, suggesting
direct binding. Similarly, a study conducted by Watanabe revealed that transgenic mice expressing
a fusion of inv and Green fluorescence protein were able to rescue laterality defects and PKD in
homozygous mutant Inv mice [120]. Moreover, evidence has shown a decrease in Inv in IgAN patients,
alongside an increase in β-catenin, indicating the hyperactivation of the canonical Wnt signalling
pathway [53].
A clinical study performed on 43 families with infantile NPHP revealed that NPHP2 was mutated
in 31% of cases and NPHP3 in 16% of cases [121]. The following phenotypes were associated with
NPHP2 mutations: diverse kidney size, cerebellar atrophy, retinitis pigmentosa, and mild liver
fibrosis [122]. Furthermore, Nphp4 can negatively regulate canonical Wnt signalling by interacting
with Inv and Dvl to regulate the stability of Dvl [123]. Histological analysis revealed that tubular
atrophy was present alongside thickened tubular basement membranes, diffuse interstitial fibrosis and
cyst formation at the cortico–medullary junction in a Nphp4 zebrafish model and cultured mammalian
kidney cells [124].
It thus becomes apparent from the above that most of the evidence linking PKD to Wnt signalling
is focused on canonical Wnt signalling (Figure 2). Such involvement is possibly mediated through
upstream Wnt components and has an effect on β-catenin transcription. This does not mean that there
is no involvement of non-canonical Wnt signalling in PKD, rather that it is hard to study non-canonical
Wnt signalling in the context of inherited kidney disease, due to the lack of good PCP antibodies and
limited samples or fully representative animal models of these diseases. Nevertheless, recent studies
have accumulated evidence on dysregulated non-canonical Wnt signalling in PKD and it remains
unclear as to whether this is a result of a shift in balance between canonical and non-canonical Wnt
signalling or two separate events on both cascades.
On the other hand, NPHP has mostly been associated with changes in non-canonical Wnt
signalling, with an initial hypothesis suggesting that the primary cilium acts as a switch that favours
non-canonical Wnt signalling. Recent findings have contested this hypothesis, as cilia have now been
shown to facilitate both canonical and non-canonical Wnt signalling. Nevertheless, increasing evidence
is being acquired on the involvement of Wnt signalling in CKD. Work on animal models as well as
human samples has demonstrated mis-regulated Wnt signalling in many genetically inherited chronic
kidney diseases. This information could shed novel insights into kidney disease mechanisms and may
hold potential therapeutic implications for this big group of diseases that overall pose a great burden
on patients’ survival and well-being worldwide.
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HEK293 Human embryonic kidney 293 cells
IgAN IgA nephropathy
Inv Inversin
IRI Ischaemia reperfusion injury
Jbn Jouberin
JS Joubert syndrome
JSRD Joubert syndrome and related disorders
KO Knockout
LOF Loss of function
Lp Loop-tail
LRP Lipoprotein receptor related protein
MDCK Madin-Darby Canine Kidney
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MGS Meckel-Gruber Syndrome
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